Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. (INMB) on February 13, 2026, covering events occurring on February 10 and February 12, 2026. The company is a biopharmaceutical firm focused on developing novel immunotherapies, with its principal executive offices located in Boca Raton, Florida.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure of specific corporate events and does not contain financial statements or quantitative financial data.
Material Changes and Regulatory Events
- UK Regulatory Submission: On February 10, 2026, the Company formally submitted a pre-submission package for its candidate drug, CORDStrom, to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).
- US FDA Meeting Minutes: On February 12, 2026, the Company received official minutes from its End-of-Phase 2 (Type B) meeting with the U.S. Food and Drug Administration (FDA).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the inherent uncertainties of regulatory interactions. The information provided in the press releases (Exhibits 99.1 and 99.2) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the same liabilities as filed financial data.
Investor Verification Checklist
- Review the full text of the press release dated February 10, 2026 (Exhibit 99.1) for details on the scope of the CORDStrom pre-submission to the MHRA.
- Review the full text of the press release dated February 12, 2026 (Exhibit 99.2) to understand the specific outcomes and next steps outlined in the FDA End-of-Phase 2 meeting minutes.
- Verify the Company's cash runway and liquidity position in the most recent 10-Q or 10-K filing, as this 8-K does not provide updated financial metrics.